{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:52:50Z","timestamp":1791219170810,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.urolonc.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T10:22:34Z","timestamp":1600251754000},"page":"229-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Second line salvage systemic therapy for advanced penile cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Jad","family":"Chahoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2020.08.001_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030683","article-title":"Adoptive cell therapy\u2014harnessing antigen-specific t cells to target solid tumours","volume":"12","author":"Chru\u015bciel","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.001_bib0002","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.urology.2014.12.049","article-title":"Treatment for metastatic penile cancer after first-line chemotherapy failure: analysis of response and survival outcomes","volume":"85","author":"Wang","year":"2015","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.001_bib0003","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.euf.2019.05.010","article-title":"The International Penile Advanced Cancer Trial (InPACT): rationale and current status","volume":"5","author":"Canter","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"24","key":"10.1016\/j.urolonc.2020.08.001_bib0004","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","article-title":"Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study","volume":"28","author":"Pagliaro","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.001_bib0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eursup.2017.07.003","article-title":"Systemic therapy for penile cancer","volume":"17","author":"Necchi","year":"2018","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.urolonc.2020.08.001_bib0006","series-title":"Penile cancer","year":"2018"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.001_bib0007","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0022-5347(17)40590-8","article-title":"cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest oncology group study","volume":"141","author":"Gagliano","year":"1989","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.001_bib0008","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.eururo.2011.08.028","article-title":"Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study","volume":"60","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"issue":"11b","key":"10.1016\/j.urolonc.2020.08.001_bib0009","doi-asserted-by":"crossref","first-page":"E661","DOI":"10.1111\/j.1464-410X.2012.11453.x","article-title":"Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis","volume":"110","author":"Di Lorenzo","year":"2012","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.urolonc.2020.08.001_bib0010","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/bjc.2013.620","article-title":"Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK\/09\/001)","volume":"109","author":"Nicholson","year":"2013","journal-title":"Br J Cancer"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2020.08.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4514","article-title":"VinCaP: a phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK\/12\/021)","volume":"36","author":"Pickering","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.001_bib0012","article-title":"Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinoma","volume":"44","year":"1979","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2020.08.001_bib0013","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdn149","article-title":"A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)","volume":"19","author":"Theodore","year":"2008","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.001_bib0014","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU guidelines on penile cancer: 2014 update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.001_bib0015","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bju.12450","article-title":"Epidermal growth factor receptor\u2013targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis","volume":"113","author":"Carthon","year":"2014","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2020.08.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017517","article-title":"Alternative HER\/PTEN\/Akt pathway activation in HPV positive and negative penile carcinomas","volume":"6","author":"Stankiewicz","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.001_bib0017","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.bjc.6603910","article-title":"Targeting HER proteins in cancer therapy and the role of the non-target HER3","volume":"97","author":"Hsieh","year":"2007","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.001_bib0018","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.soc.2013.06.008","article-title":"Targeting the PI3-kinase\/Akt\/mTOR signaling pathway","volume":"22","author":"Hassan","year":"2013","journal-title":"Surg Oncol Clin N Am"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.001_bib0019","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.eururo.2011.08.028","article-title":"Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study","volume":"60","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.urolonc.2020.08.001_bib0020","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-Cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.08.001_bib0021","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bju.14013","article-title":"First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study","volume":"121","author":"Necchi","year":"2018","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.001_bib0022","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MOU.0000000000000640","article-title":"Genetics and penile cancer: recent developments and implications","volume":"29","author":"Chahoud","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.001_bib0023","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-14-1656","article-title":"Epigenetics markers of metastasis and HPV-induced tumorigenesis in penile cancer","volume":"21","author":"Feber","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.001_bib0024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1634\/theoncologist.2015-0241","article-title":"Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations","volume":"21","author":"Ali","year":"2016","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.urolonc.2020.08.001_bib0025","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1158\/0008-5472.CAN-15-3134","article-title":"CSN1 somatic mutations in penile squamous cell carcinoma","volume":"76","author":"Feber","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.001_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-06659-1","article-title":"Multidimensional integrative analysis uncovers driver candidates and biomarkers in penile carcinoma","volume":"7","author":"Marchi","year":"2017","journal-title":"Sci Rep"},{"issue":"7_suppl","key":"10.1016\/j.urolonc.2020.08.001_bib0027","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.505","article-title":"Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors","volume":"37","author":"Chahoud","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.08.001_bib0028","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.juro.2018.09.056","article-title":"Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy","volume":"201","author":"Jacob","year":"2018","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.001_bib0029","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.urolonc.2020.08.001_bib0030","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2020.08.001_bib0031","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.urolonc.2020.08.001_bib0032","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2020.08.001_bib0033","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2016.09.003","article-title":"Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort","volume":"59","author":"Cocks","year":"2017","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.08.001_bib0034","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1269047","article-title":"Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma","volume":"6","author":"Deng","year":"2017","journal-title":"Oncoimmunology"},{"issue":"3 Part 1","key":"10.1016\/j.urolonc.2020.08.001_bib0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","article-title":"Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status","volume":"197","author":"Ottenhof","year":"2017","journal-title":"J Urol"},{"issue":"0","key":"10.1016\/j.urolonc.2020.08.001_bib0036","first-page":"214","article-title":"PD-L1 Expression in men with penile cancer and its association with clinical outcomes","volume":"0","author":"Davidsson","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.001_bib0037","article-title":"Effective combinatorial immunotherapy for penile squamous cell carcinoma","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"},{"issue":"30","key":"10.1016\/j.urolonc.2020.08.001_bib0038","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-Cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:25:09Z","timestamp":1761042309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1078143920303665"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second line salvage systemic therapy for advanced penile cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}